Valneva SE ADR VALN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
-
Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial
-
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial
-
Valneva Shares Tumble After Chikungunya Vaccine License Suspended in U.S.
Trading Information
- Previous Close Price
- $5.30
- Day Range
- $5.05–5.23
- 52-Week Range
- $5.04–12.25
- Bid/Ask
- $5.06 / $5.90
- Shares Outstanding
- 102.12M
- Market Cap
- $515.70M
- Volume/Avg
- 16,116 / 49,419
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.55
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 674
- Website
- https://www.valneva.com
Valuation
|
Metric
|
VALN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.25 |
Price/Sales | 2.55 |
Price/Cash Flow | — |
Price/Earnings
VALN
Financial Strength
|
Metric
|
VALN
|
|---|---|
Quick Ratio | 1.22 |
Current Ratio | 2.14 |
Interest Coverage | −2.40 |
Quick Ratio
VALN
Profitability
|
Metric
|
VALN
|
|---|---|
Return on Assets (Normalized) | −31.63% |
Return on Equity (Normalized) | −105.50% |
Return on Invested Capital (Normalized) | −31.52% |
Return on Assets
VALN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?%&#jW | LOCK|%sxT? | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|G<CTTh | LOCK|M!@@ | $70B | |||
| argenx SE ADR
ARGX
| LOCK|&GyY^> | LOCK|WV | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|SYD@%c | LOCK|%&R?q | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|pS?#md | LOCK|^!y | $36B | |||
| Moderna Inc
MRNA
| LOCK|jdF^$P | LOCK|t@& | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|K%^J$FCG | LOCK|Wf%v | $25B | |||
| Incyte Corp
INCY
| LOCK|y!J&^% | LOCK|Gm | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|&W?@<<& | LOCK|<<& | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|PLHHFf^ | LOCK|#p | $17B |
United States